Skip to content

Market Research - Acceptability Trial for a New PKU Amino Acid Based Protein Substitute

Market Research - Acceptability Trial for a New PKU Amino Acid Based Protein Substitute (Dr Schär Medical Nutrition - Mevalia Amino Acids) Mevalia PKU Motion 10 - Tropical or Red Fruits Mevalia PKU Motion 20 - Tropical or Red Fruits

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04309331
Enrollment
12
Registered
2020-03-16
Start date
2018-07-01
Completion date
2018-09-19
Last updated
2020-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inborn Errors of Metabolism, Metabolic Disease, Phenylketonurias, PKU

Brief summary

The aim of this study is to demonstrate that a new protein substitute is acceptable and well tolerated in children with PKU.

Interventions

DIETARY_SUPPLEMENTMotion

Amino acid based protein substitute

Sponsors

Dr. Schär AG / SPA
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
3 Years to 16 Years
Healthy volunteers
No

Inclusion criteria

* Diagnosis of PKU or PKU variant requiring a phenylalanine-free protein substitute * Subjects who are already taking a phenylalanine-free protein substitute and are willing to try the study product for 7 days * Patients aged 3 years of age to adulthood * Written informed consent obtained from parental caregiver

Exclusion criteria

* Presence of serious concurrent illness * Investigator's uncertainty about the willingness or ability of the patient to comply with the protocol requirements * Participation in any other studies involving investigational or marketed products concomitantly or within two weeks prior to entry into the study. * Any patients having taken antibiotics over the previous 2 weeks leading up to the study. * Patients less than 3 years of age.

Design outcomes

Primary

MeasureTime frameDescription
Gastrointestinal tolerance7 daysQuestionnaire detailing any GI symptoms, severity and change from usual • The collection of daily data about the gastro-intestinal tolerance of the protein substitute.
Product compliance7 daysDaily questionnaire on amounts offered and amounts actually consumed, compared to recommended amount.
Product palatability7 daysQuestionnaire data captured to evaluate taste
Product acceptability7 daysBrief tick-box questionnaire on overall liking and acceptability of product

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026